WeChat Program Improves Weight Loss and Steatosis

Researchers at Xinhua Hospital in Shanghai report a 6-month randomized controlled trial (n=89) comparing a WeChat mini-program lifestyle intervention to standard care among overweight or obese adults with MAFLD. The intervention group achieved greater weight loss (60% ≥5%, 24.4% ≥10%) and improved hepatic steatosis (CAP reduction/normalization) and metabolic markers. The study suggests a scalable, low-cost approach suitable for primary care.